MK-677 (Ibutamoren) is an oral ghrelin receptor agonist studied for sustained GH pulsatility, IGF-1 production, sleep quality, and anabolic effects. Physician-reviewed. Prescription required.
MK-677 (Ibutamoren) is an orally active growth hormone secretagogue that mimics the action of Ghrelin. Its primary mechanism is activation of the Growth Hormone Secretagogue Receptor, which stimulates endogenous secretion of Growth Hormone and subsequently increases Insulin-like Growth Factor 1.
MK-677 has been studied for its role in increasing GH pulsatility, elevating IGF-1, improving slow-wave sleep, supporting lean mass, and stimulating appetite. Its oral bioavailability distinguishes it from peptide-based GH secretagogues. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| Ghrelin receptor (GHSR1a) agonism | Stimulates GH release |
| PLC/IP3/Ca²⁺ signaling | Triggers pituitary hormone secretion |
| Increased GH pulsatility | Sustained GH elevation |
| IGF-1 production | Anabolic and tissue growth effects |
| Hypothalamic appetite signaling | Increased hunger |
| Sleep architecture modulation | Increased slow-wave sleep |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with MK-677 / Ibutamoren protocol candidates in clinical practice:
GH Optimization
Individuals with GH decline seeking oral secretagogue therapy under physician supervision.
Sleep Quality
Individuals with sleep disruption where GH-mediated slow-wave sleep enhancement may be clinically relevant.
Body Composition
Individuals pursuing physician-reviewed lean mass and fat metabolism support via GH/IGF-1 pathway.
Longevity Protocol
Individuals with longevity protocols adding physician-reviewed oral GH secretagogue support.
Determine your candidacy
A physician will review your intake and make eligibility determination within 24–48 hours.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
10–25 mg/day
Administration
Oral
Duration
12–24 weeks (physician-determined)
Frequency
Once daily at bedtime (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.
Begin your MK-677 / Ibutamoren protocol.
Complete your intake. Physician review within 24–48 hours.
Physician-reviewed. Pharmacy-dispensed. Prescription required before any order is fulfilled.
Prescription required. Results may vary. Individual outcomes may differ.
MK-677 (Ibutamoren) is a growth hormone secretagogue used for muscle building, fat loss, improved sleep quality, and anti-aging. It works by increasing GH and IGF-1 levels.
Some patients experience mild water retention, especially in the first few weeks. This typically resolves as the body adjusts. A physician can guide dosing to minimize this.
MK-677 is taken orally as a capsule — one of the few GH secretagogues available in capsule form. Verum Health offers 12.5mg and 25mg capsule strengths.
Yes. MK-677 is commonly stacked with CJC-1295/Ipamorelin for amplified GH effects, or with BPC-157 for combined recovery and body composition protocols.